The FDA will hold a public workshop Oct. 27 at its White Oak campus in Silver Spring, Md., to address challenges in evaluating products to treat pediatric heart failure. The discussion will include endpoints, study populations, statistical methods, alternative trial designs, extrapolation of adult efficacy data and the use of registry data, according to a notice published in Thursday's Federal Register. Pre-registration is required.